Citius Pharmaceuticals, Inc. (CTXR)
0.5316
-0.01
(-1.59%)
USD |
NASDAQ |
Oct 02, 16:00
0.5315
0.00 (0.00%)
After-Hours: 20:00
Citius Pharmaceuticals EPS Diluted (Quarterly) : -0.3387 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3387 |
| March 31, 2026 | -0.9488 |
| December 31, 2025 | -0.3824 |
| September 30, 2025 | -0.4405 |
| June 30, 2025 | -0.7986 |
| March 31, 2025 | -1.272 |
| December 31, 2024 | -1.304 |
| September 30, 2024 | -1.589 |
| June 30, 2024 | -1.567 |
| March 31, 2024 | -1.343 |
| December 31, 2023 | -1.452 |
| September 30, 2023 | -1.746 |
| June 30, 2023 | -1.378 |
| March 31, 2023 | -1.799 |
| December 31, 2022 | -0.6145 |
| September 30, 2022 | -1.367 |
| June 30, 2022 | -1.516 |
| March 31, 2022 | -1.294 |
| December 31, 2021 | -1.580 |
| September 30, 2021 | -0.8495 |
| June 30, 2021 | -1.326 |
| March 31, 2021 | -1.074 |
| December 31, 2020 | -3.665 |
| September 30, 2020 | -1.854 |
| June 30, 2020 | -2.812 |
| Date | Value |
|---|---|
| March 31, 2020 | -3.224 |
| December 31, 2019 | -3.701 |
| September 30, 2019 | -4.00 |
| June 30, 2019 | -5.006 |
| March 31, 2019 | -4.913 |
| December 31, 2018 | -5.453 |
| September 30, 2018 | -4.394 |
| June 30, 2018 | -4.75 |
| March 31, 2018 | -11.00 |
| December 31, 2017 | -9.50 |
| September 30, 2017 | -11.00 |
| June 30, 2017 | -12.25 |
| March 31, 2017 | -15.00 |
| December 31, 2016 | -11.25 |
| September 30, 2016 | -13.28 |
| June 30, 2016 | -18.75 |
| March 31, 2016 | -7.50 |
| December 31, 2015 | -15.00 |
| September 30, 2015 | -9.982 |
| June 30, 2015 | -11.25 |
| March 31, 2015 | -3.75 |
| December 31, 2014 | -11.25 |
| June 30, 2014 | -0.21 |
| March 31, 2014 | -0.336 |
| December 31, 2013 | -0.012 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 0.356 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 2.268 |
| Eli Lilly & Co. | 7.939 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -11.92M |
| Revenue (Quarterly) | 1.494M |
| Total Expenses (Quarterly) | 10.36M |
| Enterprise Value | 14.06M |
| Gross Profit Margin (Quarterly) | -48.09% |
| Profit Margin (Quarterly) | -797.9% |
| Earnings Yield | -397.0% |
| Normalized Earnings Yield | -397.01 |